Janux Therapeutics (JANX) Projected to Post Earnings on Thursday

Janux Therapeutics (NASDAQ:JANX) will likely be issuing its Q3 2026 results after the market closes on Thursday, November 5th. Analysts expect Janux Therapeutics to post earnings of ($0.4737) per share and revenue of $8.03 million for the quarter. Investors can check the company’s upcoming Q3 2026 earnings overview page for the latest details on the call scheduled for Friday, November 13, 2026 at 4:00 PM ET.

Janux Therapeutics (NASDAQ:JANX) last issued its quarterly earnings results on Thursday, August 6th. The company reported ($0.35) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.25) by ($0.10). The company had revenue of $10.27 million for the quarter, compared to the consensus estimate of $19.07 million. On average, analysts expect Janux Therapeutics to post ($1.70) EPS for the current fiscal year and ($2.64) EPS for the next fiscal year.

Janux Therapeutics Trading Down 0.1%

Shares of JANX opened at $17.46 on Tuesday. The company has a market cap of $1.07 billion, a price-to-earnings ratio of -10.65 and a beta of 2.40. The business’s fifty day simple moving average is $17.60 and its two-hundred day simple moving average is $15.34. Janux Therapeutics has a 12 month low of $12.12 and a 12 month high of $35.34.

Wall Street Analysts Forecast Growth

A number of equities analysts recently issued reports on the stock. HC Wainwright reissued a “buy” rating on shares of Janux Therapeutics in a report on Monday, October 19th. Wolfe Research raised Janux Therapeutics from a “peer perform” rating to an “outperform” rating and set a $23.00 price objective for the company in a research note on Monday, August 24th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Janux Therapeutics in a research report on Friday, October 16th. Stifel Nicolaus set a $35.00 target price on Janux Therapeutics in a research note on Friday, August 7th. Finally, Guggenheim cut their target price on shares of Janux Therapeutics from $58.00 to $55.00 and set a “buy” rating for the company in a research note on Friday, August 7th. One research analyst has rated the stock with a Strong Buy rating, ten have assigned a Buy rating, two have issued a Hold rating and two have given a Sell rating to the company. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $36.46.

About Janux Therapeutics

Janux Therapeutics, Inc is a clinical-stage biopharmaceutical company developing immune-based medicines for the treatment of cancer and autoimmune diseases. The company’s research is focused on designing therapies that selectively activate the immune system in diseased tissue while limiting activity in healthy tissue.

Janux’s proprietary technology platform is designed to create tumor-activated T-cell engager therapies and other immunomodulators. These medicines are engineered to remain relatively inactive in the circulation and become activated in the tumor microenvironment, with the goal of improving the therapeutic window of immune therapies.